Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intranodal Administration of an RNA-based Cancer Vaccine Targeting Two Tumor-associated Antigens in Patients With Advanced Melanoma

Trial Profile

Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intranodal Administration of an RNA-based Cancer Vaccine Targeting Two Tumor-associated Antigens in Patients With Advanced Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs RBL 001 (Primary) ; RBL 002 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker
  • Acronyms MERIT
  • Sponsors BioNTech
  • Most Recent Events

    • 21 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 26 Jan 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 26 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top